HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rose more than 5%, and 9 drugs including SHR-9839 for injection were approved for clinical trials.

Jiangsu Hengrui Pharmaceuticals (01276) rose by more than 5%, as of the time of writing, it increased by 5.08%, reaching HK$69.3, with a turnover of HK$141 million. On the news front, on November 21, Jiangsu Hengrui Pharmaceuticals issued an announcement that Jiangsu Hengrui Pharmaceuticals Co., Ltd. and its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceuticals Co., Ltd., and Shanghai Shengdi Pharmaceuticals Co., Ltd. have received approval from the National Medical Products Administration to conduct clinical trials of injectable SHR-9839(sc), injectable SHR-A2009, injectable SHR-1826, HRS-4642 injectable solution, adalimumab injectable solution, injectable rituximab, injectable SHR-A2102, HRS-7058 capsules, and HRS-7058 tablets. The clinical trials will be conducted in the near future.